Julie Krop, serving as a director at Aquestive Therapeutics, Inc. (NASDAQ:AQST), completed a sale of the company's common stock on June 23, 2026. The transaction involved the disposition of 25,000 shares, resulting in proceeds of $125,392. The execution price for these shares was recorded at $5.0157 per share.
This divestment activity was directly preceded by the exercise of 25,000 non-qualified stock options. These options, which were granted on June 22, 2022, and had reached full vesting status prior to the transaction, were acquired at a cost of $0.7132 per share, totaling $17,830. Both the option exercise and the subsequent sale were finalized on the same calendar day. Following the completion of these transactions, Julie Krop's direct holding of Aquestive Therapeutics common stock stands at zero shares.
All trading activities were conducted in accordance with a pre-arranged Rule 10b5-1 trading plan. The timing of this sale coincides with a notable upward trajectory in the company's stock price. Over the preceding twelve months, the stock has appreciated by 57%. In the more recent seven-day period leading up to the transaction, the shares gained an additional 13.5%.
Market analysis provided by InvestingPro indicates that AQST currently trades at a valuation slightly above its calculated Fair Value. An InvestingPro Tip within the analysis notes that the Relative Strength Index (RSI) metric suggests the stock is currently in overbought territory. Investors seeking further detailed metrics can access nine additional ProTips and comprehensive analysis through the platform's detailed Pro Research Report.
The insider transaction follows the release of Aquestive Therapeutics' financial results for the first quarter of 2026. The company reported earnings that surpassed analyst expectations. The reported earnings per share (EPS) was -$0.07, representing a 46.15% positive surprise compared to the anticipated EPS of -$0.13. Revenue for the quarter reached $14.4 million, significantly exceeding the predicted figure of $10.9 million. This revenue performance reflects a 66% year-over-year increase.
Regarding strategic developments, Aquestive Therapeutics confirmed the timeline for the resubmission of the Anaphylm New Drug Application (NDA), which is scheduled for the third quarter of 2026. The company also reiterated its financial guidance for the full year 2026. In terms of analyst activity, Citizens maintained a Market Outperform rating for Aquestive, establishing a price target of $10.00.